Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Cancer

Volumn 124, Issue 2, 2018, Pages 271-277

  Pillai, Rathi N ^a   Behera, Madhusmita ^a   Owonikoko, Taofeek K ^a   Kamphorst, Alice O ^a   Pakkala, Suchita ^a   Belani, Chandra P ^b   Khuri, Fadlo R ^a   Ahmed, Rafi ^a   Ramalingam, Suresh S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adverse events; immune checkpoint inhibitors; immune related adverse events; non small cell lung cancer (NSCLC)

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CHEMOTHERAPY; CLINICAL FEATURE; COLITIS; CONFIDENCE INTERVAL; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; MONOTHERAPY; NEPHRITIS; NON SMALL CELL LUNG CANCER; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85030650022     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31043     Document Type: Review

References (34)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
2. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687.
3. Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7-14.
4. Shimoji M, Shimizu S, Sato K, et al. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer. 2016;98:69-75.
5. Sun JM, Zhou W, Choi YL, et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol. 2016;11:1003-1011.
6. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol. 2013;8:803-805.
7. Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4:203-208.
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
9. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
10. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
11. Fehrenbacher L, Spira A, Ballinger M, et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.
12. Reck M, Rodriguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
13. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.
14. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559-574.
15. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
16. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
17. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-2012.
18. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
19. Sakai H, Nishio M, Hida T, et al. Phase II studies of nivolumab in patients with advanced squamous (SQ) or non-squamous (NSQ) non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51:S110-S111.
20. Bauer TM, McCleod M, Chandler JC, et al. An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens [abstract]. J Clin Oncol. 2015;33. Abstract 3013. http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3013
21. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976-983.
22. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980-2987.
23. Socinski M, Creelan B, Horn L, et al. CheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1) positive NSCLC. Ann Oncol. 2016;27. https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdw435.39/2800548/NSCLC-metastaticCheckMate-026-A-phase-3-trial-of
24. Brahmer J, Rizvi N, Lutsky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PDL1 antibody, in patients with NSCLC [abstract]. J Clin Oncol. 2014;32. Abstract 8021. http://meetinglibrary.asco.org/record/92535/abstract
25. Rizvi N, Brahmer J, Ou SH, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015;33. Abstract 8032. http://meetinglibrary.asco.org/record/108561/abstract
26. Spigel DR, Gettinger S, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2013;31. Abstract 8008. http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.8008
27. Horn L, Spigel DR, Gettinger S, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase 1a study [abstract]. J Clin Oncol. 2015;33. Abstract 8029. http://meetinglibrary.asco.org/record/108531/abstract
28. Spigel DR, Chaft JE, Gettinger S, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015;33. Abstract 8028. http://meetinglibrary.asco.org/record/108536/abstract
29. Besse B, Johnson M, Janne PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51:S717-S718. http://www.ejcancer.com/article/S0959-8049(16)31938-4/abstract
30. Verschraegen CF, Chen F, Spigel DR, et al. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: safety, clinical activity, and PD-L1 expression [abstract]. J Clin Oncol. 2016;34. Abstract 9036. http://meetinglibrary.asco.org/record/123543/abstract
31. Gulley JL, Spigel DR, Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase Ib, open-label expansion trial in patients progressing after platinum-based chemotherapy [abstract]. J Clin Oncol. 2015;33. Abstract 8034. http://meetinglibrary.asco.org/record/108446/abstract
32. Antonia S, Kim S, Spira AI, et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non-small-cell lung cancer [abstract]. J Clin Oncol. 2016;34. Abstract 9029. http://meetinglibrary.asco.org/record/123502/abstract
33. Barlesi F, Park K, Ciardello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]. Ann Oncol. 2016;27. Abstract LBA44_PR. http://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/Primary-analysis-from-OAK-a-randomized-phase-III-study-comparing-atezolizumab-with-docetaxel-in-2L-3L-NSCLC
34. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10:e0130142.